25:
320:
117:
603:
481:
Roche announced in June 2018 that there would be no further development of taselislib following the top line results of the Phase III "Sandpiper" study. Currently running clinical trials were continued for patients exhibiting benefit.
393:
695:
572:
129:
651:
525:"Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations"
435:
InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)
54:
675:
585:
407:
670:
644:
465:
637:
427:
94:
573:"Roche dumps its PhIII PI3K effort on taselisib after researchers track poor survival edge, harsh side effects for breast cancer"
153:
586:
https://clinicaltrials.gov/ct2/results?term=taselisib&Search=Apply&recrs=d&age_v=&gndr=&type=&rslt=
239:
70:
299:
46:
50:
690:
685:
499:
680:
288:
35:
39:
315:
617:
174:
63:
554:
458:
228:
74:
621:
183:
544:
536:
336:
59:
523:
Zumsteg ZS, Morse N, Krigsfeld G, Gupta G, Higginson DS, Lee NY, et al. (April 2016).
248:
614:
319:
610:
549:
524:
462:
664:
208:
540:
116:
602:
369:
219:
558:
500:"Definition of taselisib - NCI Drug Dictionary - National Cancer Institute"
108:
415:
CC1=NN(C(=N1)C2=CN3CCOC4=C(C3=N2)C=CC(=C4)C5=CN(N=C5)C(C)(C)C(=O)N)C(C)C
472:
194:
475:
279:
268:
392:
383:
469:
259:
457:) is a former cancer drug candidate that was in development by
18:
304:
57:
and tools are available to assist in formatting, such as
625:
381:
368:
335:
330:
298:
278:
258:
238:
218:
193:
173:
144:
128:
123:
207:
182:
696:Antineoplastic and immunomodulating drug stubs
645:
8:
107:
38:, which are uninformative and vulnerable to
53:and maintains a consistent citation style.
652:
638:
318:
227:
115:
548:
247:
95:Learn how and when to remove this message
491:
432:
412:
314:
158:
106:
287:
7:
676:Phosphoinositide 3-kinase inhibitors
599:
597:
466:phosphoinositide 3-kinase inhibitor
267:
198:
45:Please consider converting them to
624:. You can help Knowledge (XXG) by
165:-pyrazol-1-yl}-2-methylpropanamide
14:
601:
353:
347:
23:
440:Key:BEUQXVWXFDOSAQ-UHFFFAOYSA-N
671:Drugs not assigned an ATC code
359:
341:
49:to ensure the article remains
1:
541:10.1158/1078-0432.CCR-15-2245
712:
596:
331:Chemical and physical data
423:
403:
161:2-{4-benzoxazepin-9-yl]-1
149:
114:
529:Clinical Cancer Research
453:(development code:
111:
633:
632:
448:
447:
394:Interactive image
300:CompTox Dashboard
105:
104:
97:
55:Several templates
16:Chemical compound
703:
654:
647:
640:
615:immunomodulatory
605:
598:
588:
583:
577:
576:
569:
563:
562:
552:
520:
514:
513:
511:
510:
496:
396:
376:
361:
355:
349:
343:
323:
322:
308:
306:
291:
271:
251:
231:
211:
201:
200:
186:
119:
112:
110:
100:
93:
89:
86:
80:
78:
67:
27:
26:
19:
711:
710:
706:
705:
704:
702:
701:
700:
691:Abandoned drugs
661:
660:
659:
658:
594:
592:
591:
584:
580:
571:
570:
566:
522:
521:
517:
508:
506:
498:
497:
493:
488:
444:
441:
436:
431:
430:
419:
416:
411:
410:
399:
374:
364:
358:
352:
346:
326:
302:
294:
274:
254:
234:
214:
197:
189:
169:
166:
157:
156:
140:
101:
90:
84:
81:
69:
58:
44:
28:
24:
17:
12:
11:
5:
709:
707:
699:
698:
693:
688:
686:Benzoxazepines
683:
678:
673:
663:
662:
657:
656:
649:
642:
634:
631:
630:
611:antineoplastic
606:
590:
589:
578:
564:
535:(8): 2009–19.
515:
490:
489:
487:
484:
476:p110α (PIK3CA)
468:targeting the
463:small molecule
446:
445:
443:
442:
439:
437:
434:
426:
425:
424:
421:
420:
418:
417:
414:
406:
405:
404:
401:
400:
398:
397:
389:
387:
379:
378:
372:
366:
365:
362:
356:
350:
344:
339:
333:
332:
328:
327:
325:
324:
316:DTXSID00155842
311:
309:
296:
295:
293:
292:
284:
282:
276:
275:
273:
272:
264:
262:
256:
255:
253:
252:
244:
242:
236:
235:
233:
232:
224:
222:
216:
215:
213:
212:
204:
202:
191:
190:
188:
187:
179:
177:
171:
170:
168:
167:
160:
152:
151:
150:
147:
146:
142:
141:
139:
138:
134:
132:
126:
125:
121:
120:
103:
102:
47:full citations
31:
29:
22:
15:
13:
10:
9:
6:
4:
3:
2:
708:
697:
694:
692:
689:
687:
684:
682:
681:Propionamides
679:
677:
674:
672:
669:
668:
666:
655:
650:
648:
643:
641:
636:
635:
629:
627:
623:
620:article is a
619:
616:
612:
607:
604:
600:
595:
587:
582:
579:
574:
568:
565:
560:
556:
551:
546:
542:
538:
534:
530:
526:
519:
516:
505:
501:
495:
492:
485:
483:
479:
477:
474:
471:
467:
464:
460:
456:
452:
438:
433:
429:
422:
413:
409:
402:
395:
391:
390:
388:
385:
380:
373:
371:
367:
340:
338:
334:
329:
321:
317:
313:
312:
310:
301:
297:
290:
289:ChEMBL2387080
286:
285:
283:
281:
277:
270:
266:
265:
263:
261:
257:
250:
246:
245:
243:
241:
237:
230:
226:
225:
223:
221:
217:
210:
206:
205:
203:
196:
192:
185:
181:
180:
178:
176:
172:
164:
159:
155:
148:
143:
136:
135:
133:
131:
127:
124:Clinical data
122:
118:
113:
99:
96:
88:
76:
75:documentation
72:
65:
64:documentation
61:
56:
52:
48:
43:
41:
37:
32:This article
30:
21:
20:
626:expanding it
608:
593:
581:
567:
532:
528:
518:
507:. Retrieved
503:
494:
480:
454:
450:
449:
184:1282512-48-4
162:
91:
82:
71:Citation bot
33:
377: g·mol
145:Identifiers
85:August 2022
665:Categories
509:2017-01-10
504:Cancer.gov
486:References
461:. It is a
382:3D model (
370:Molar mass
249:L08J2O299M
220:ChemSpider
175:CAS Number
154:IUPAC name
51:verifiable
451:Taselisib
109:Taselisib
36:bare URLs
559:26589432
455:GDC-0032
229:29315044
209:51001932
130:ATC code
40:link rot
550:4870591
473:isoform
375:460.542
337:Formula
195:PubChem
557:
547:
408:SMILES
280:ChEMBL
269:D11774
60:reFill
609:This
459:Roche
428:InChI
384:JSmol
34:uses
622:stub
618:drug
555:PMID
470:PI3K
260:KEGG
240:UNII
137:None
68:and
613:or
545:PMC
537:doi
305:EPA
199:CID
667::
553:.
543:.
533:22
531:.
527:.
502:.
478:.
351:28
345:24
653:e
646:t
639:v
628:.
575:.
561:.
539::
512:.
386:)
363:2
360:O
357:8
354:N
348:H
342:C
307:)
303:(
163:H
98:)
92:(
87:)
83:(
79:.
77:)
73:(
66:)
62:(
42:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
